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Introduction
Thyroid hormones (THs) are key regulators of cardiac physiology. Firstly, directly by enhancing fatty acids (FAs) and glucose utilization as a compensation for increased myocardial workload [increased heart rate (HR) or systolic pressure]. Secondly, several genes encoding important structural and regulatory proteins in the myocardium, including myosin isoform expression, calcium cycling proteins and protein kinases, are thyroid hormone responsive [1, 2] . These direct effects of T 3 cellular actions are mediated by its nuclear and membrane receptors (α and/or β THR receptors). It seems that in heart triiodothreonine effects result from the binding of T 3 to nuclear thyroid hormone receptors, which belong to the superfamily of steroid hormone receptors [3] . These effects are, at least partially, controlled by the peroxisome proliferator-activated receptors (PPARα, β/δ and γ) and their co-activators (i.e. peroxisome proliferator-activated receptor-γ coactivator-1α -PGC-1α/PPARGC1A) or corepressors (i.e. nuclear receptor interacting protein 1 -NRIP1/RIP140) [4, 5] . In opposite, the non-genomic effects result in activation of different intracellular signaling pathways involving Akt/protein B (PKB) and AMP activated protein kinase (AMPK) that activate the transport of ions (calcium, sodium and potassium) across the plasma membrane, glucose transport, and mitochondrial gene expression [6, 7] . Activation of AMPK and Akt/PKB protein can be considered as rapid metabolic response, leading to increased fatty acid oxidation and glycolysis via enzyme phosphorylation and gene transcription initiation [8, 9] . It was previously shown that T 3 can induce activation of specific kinases leading to phosphorylation of AMPK in skeletal muscle tissue [8, 10] as well as PKB, which has been shown to be activated through phosphorylation by T 3 in rat cardiomyocyes [11] . So far, there is no evidence that T 3 may interact or influence the behavior of myocardial sphingolipids. This class of lipids belong to a group of lipid-derived molecules, containing a sphingoid base as a backbone to which is attached a single fatty acid (FA) side-chain of varying length and degree of saturation [12, 13] . Among sphingolipids, most of the interest has been placed to the biological function of ceramide, because of its involvement in lipotoxicity, apoptosis, proliferation, differentiation, growth arrest, inflammation and pathogenesis of insulin resistance [14] [15] [16] [17] . The amount of ceramide is determined by a balance between the rate of its formation and degradation. Ceramide is generated through de novo synthesis, salvage pathway (by ceramidases), and sphingomyelin cycle (by sphingomyelinases) (Fig. 1) [14, 15, 18] . The first and rate-limiting step of de novo process is catalyzed by the enzyme serine palmitoyltransferase (SPT), to form 3-ketosphinganine [12, 13, 19, 20] . The final two steps of this pathway involve the generation of dihydroceramide from sphinganine (SFA), by the action of dihydroceramide synthase, and its subsequent conversation into ceramide by dihydroceramide desaturase [13, 21] . In addition, the ceramide can be further modified into alternative forms, including glucosylceramide and ceramide 1-phosphate [13] . In contrast, degradation of ceramide occurs mainly by its deacylation and formation of sphingosine in a reaction catalyzed by specific ceramidases: acid (aCDase), neutral (nCDase) and alkaline (alCDase). However, it is well known that acid ceramidase activity in the rat heart is definitely lower than the activity of alkaline or neutral ceramidase isoforms of this enzyme. Therefore, this isoform probably does not play significant role in the generation of myocardial ceramide pool [22] . Finally, sphingosine can be phosphorylated by sphingosine kinase to form sphingosine-1-phosphate (S1P). There are also differences for the expression of sphingosine kinase isoforms. It is noteworthy that SphK1 is dominant subtype in the human myocardium, whereas the rodent heart expresses predominantly SphK2 [22] . Besides de novo synthesis, ceramide can also be produced by the action of sphingomyelinases (SMases) (Fig. 1) . Therefore, ceramide level may be regulated by distinct mechanisms and in distinct compartments. In support of the notion are the data indicating that hypothyreosis results in a reduction in the content of CER in the skeletal muscles, liver and heart [23] . On other hand, CER has been proposed to be a mediator of cardiomyocyte apoptosis induced by ischemia-reperfusion. It was shown that hypoxia-reoxygenation rapidly activates neutral sphingomyelinase in rat cardiomyocytes which results in the accumulation of CER [24] .
However, so far there are no data available on the effect of hyperthyroidism on the metabolism of sphingolipids in the heart. Therefore, hyperthyroidism was induced in rats in vivo and consequently the activity of key enzymes of ceramide metabolism (neutral sphingomyelinase, acid sphingomyelinase, neutral ceramidase, alkaline ceramidase) as well as the content of sphingolipid metabolism products (sphinganine, ceramide, sphingosine, sphingosine-1-phosphate and sphingomyelin) was measured.
Materials and Methods

Animals and study design
All animal experiments were conducted in accordance with the guidelines of the Ethical Committee for Animal Experiments at the Medical University of Bialystok. Adult male Wistar rats (250-280 g) were housed under controlled conditions (21 °C ± 2, 12 h light/12 h dark cycle) with unrestricted access to water and standard laboratory rat chow. The animals were randomly divided into two groups: control (n=8) and treated with triiodothyronine (T 3 ) (n=8). Triiodothyronine (Sigma Aldrich, St. Louis, MO) was injected subcutaneously at a dose of 50µg/100g of body weight, daily for 10 days, as reported elsewhere [25] . This dose is commonly used to mimic hyperthyroidism in humans [26] . Control animals were treated with 0,9% saline. The animals were in a fasted state at the time of sacrifice and tissue collection. 24 h after the last T 3 injection, the rats were anesthetized by intraperitoneal injection of pentobarbital with a dose of 80mg/kg of body weight.
Samples of the left ventricle were excised, cleaned of the blood and immediately freeze-clamped with aluminum tongs precooled in liquid nitrogen. Blood taken from the abdominal aorta was collected to sodium-heparinized tubes, centrifuged, then the plasma was separated and flash-frozen in liquid nitrogen. All samples were stored at -80°C until further analysis.
Plasma triiodothyronine (T3) and glucose concentration T 3 concentration was measured in plasma, with commercially available kit, according to the manufacturer's instruction (Rat Triiodothyronine, T 3 ELISA kit, EIAab). Glucose was measured by the enzymatic method using a 2300 STAT Plus glucose analyzer (YSI, US). 
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Concentration of free fatty acids and sphingomyelin
Plasma levels of free fatty acids (FFAs) and intramuscular sphingomyelin (SM) were analyzed by gas-liquid chromatography (GLC). Studied lipids were extracted using the Folch method of extraction [27] modified according to van der Vusse et al. [28] . Briefly, heart muscle and serum samples were extracted in chloroform-methanol (2:1, vol/vol) containing butylated hydroxytoluene (0.01%) as an antioxidant and heptadecanoic acid as an internal standard. Then the lipid samples were separated by thin-layer chromatography silica plates (Kieselgel 60, 0.22 mm, Merck, Darmstadt, Germany) with a heptane: isopropyl ether: acetic acid (60:40:3, vol/vol/vol) resolving solution. Lipid bands were visualized by spraying with a 0.2% solution of 3'7'-dichlorofluorescin in methanol and identified under ultraviolet light using standards on the plates. Then the gel bands corresponding to the sphingomyelin were scraped off the plate, transferred into screw tubes which contained pentadecanoic acid (Sigma-Aldrich, St. Louis, MO) as an internal standard and transmethylated with BF 3 /methanol. Also FFAs were transmethylated with BF 3 / methanol. The fatty acid methyl esters (FAMEs) were dissolved in hexane and analyzed by GLC. A HewlettPackard 5890 Series II gas chromatograph with Varian CP-SIL capillary column (100 m, internal diameter of 0.25 mm) and flame-ionization detector was used. According to the retention times of standards, the individual long-chain fatty acids were quantified. The content of sphingomyelin was estimated as the sum of the particular fatty acid species and expressed in nanomoles per miligram of protein. Serum levels of FFA was expressed in nanomoles per milliliter of the plasma.
Concentration of sphingoid bases
Concentration of sphingosine, sphinganine, S1P was measured using the method previously described by Min et al. [29] . Briefly, internal standards (10 pmol of C17-sphingosine and 30 pmol of C17-S1P, Avanti Polar Lipids, USA) were added to the samples before sonication. The dried lipid residues were redissolved in ethanol and sphingoid bases were converted to their o-phthalaldehyde derivatives and analyzed using HPLC system (ProStar, Varian, USA) equipped with a fluorescence detector and C18 reversed-phase column (Varian, OmniSpher 5, 4.6 x 150 mm). The isocratic eluent composition of acetonitrile (Merck, Darmstadt, Germany), water (9 : 1, v/v) and flow rate of 1 mL/min were used. The column temperature was maintained at 30°C.
Concentration of ceramide
A small volume (50 µL) of the chloroform phase containing lipids extracted as described above was transferred to a fresh tube containing 40 pmol of N-palmitoyl-D-erythro-sphingosine (C17 base) as an internal standard. The samples were evaporated under a nitrogen stream, redissolved in 1,2 mL of 1M KOH in 90% methanol and heated at 90°C for 60 min to convert ceramide into sphingosine. This digestion procedure does not convert complex sphingolipids, such as sphingomyelin, galactosylceramide or glucosylceramide, into free sphingoid bases [30] . Samples were then partitioned by the addition of chloroform and water. The upper phase was discarded and the lower phase was evaporated under nitrogen. The content of free sphingosine liberated from ceramide was then analyzed using HPLC as described above. The calibration curve was prepared using N-palmitoylsphingosine (Avanti Polar Lipids) as a standard. The chloroform extract used for the analysis of ceramide contains small amounts of free sphingoid bases. Therefore, the concentration of ceramide was corrected for the level of free sphingosine determined in the same sample.
The activity of neutral SMase and acid SMase
The protein level was estimated in homogenate prior to enzymatic analysis with the BSA protein assay kit (Sigma-Aldrich, St. Louis, MO). As a standard, bovine serum albumin (Sigma-Aldrich, St. Louis, MO) was used.
The activity of neutral and acidic isoforms of sphingomyelinase was determined accordingly to Liu et al. [31] with the use of radiolabeled substrate [N-methyl- 
The activity of neutral CDase and alkaline CDase
The activity of neutral and alkaline ceramidases was measured by the method of Nikolova-Karakashian and Merrill [32] . The activity of the enzymes was determined with the use of radiolabeled [N-palmitoyl-
Results
General characteristics
As previously reported by us [18, 33] and others [1, 34] , prolonged thyroid hormone treatment caused only a small decrease in body weight (Table 1 , -16%, P>0.05), but induced heart hypertrophy as indicated by either increased heart weight and/or size (compared to tibia, data not shown). Furthermore, plasma FFA, glucose and T 3 content was significantly increased (Table 1 , 5-fold, +22% and 4,8-fold, P<0.05, respectively) after T 3 administration.
The content of heart sphingolipids Sustained T 3 provision led to a substantial increase (~1,5-fold) in sphinganie level, which is an important substrate for de novo ceramide synthesis ( Fig.2A , P < 0.05). As a consequence, significant enhancement in the content of ceramide (Fig.2B, +28% , P < 0.05) accompanied by a significant increase in sphingosine level (Fig.2C, +80% , P < 0.05) was noticed. Furthermore, we observed pronounced elevation (~5-fold) of sphingomyelin Table 1 . General features and plasma measurements of the experimental animals. The animals were divided into two groups: control and treated with T 3 . T 3 was injected subcutaneously with a dose of 50µg/100g of body weight, daily for 10 days, while control animals were treated with 0,9% saline. Data are shown as mean ± SD (n=8 in each group). *P < 0.05 statistically significant difference vs. T 3 treatment
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The activities of key enzymes implicated in sphingolipids metabolism
In the next step we checked which enzymes and proteins, involved in regulation of cardiac sphingolipid metabolism, were substantially changed by hyperthyroidism and The animals were divided into two groups: control and treated with T 3 . T 3 was injected subcutaneously with a dose of 50µg/100g of body weight, daily for 10 days, while control animals were treated with 0,9% saline. T 3 -triodothyronine. Data are shown as mean ± SD (n=8 in each group). *P < 0.05 statistically significant difference vs. T 3 treatment.
Fig. 3. Effect of hyperthyroidism on the myocardial activity of: (A) alkaline and neutral ceramidases and (B)
neutral and acid sphingomyelinases. The animals were divided into two groups: control and treated with T 3 . T 3 was injected subcutaneously with a dose of 50µg/100g of body weight, daily for 10 days, while control animals were treated with 0,9% saline. nCDase -neutral ceramidase, alCDase -alkaline ceramidese, nSMase -neutral sphingomyelinase, aSMase -acid sphingomyelinase, T 3 -triodothyronine. Data are shown as mean ± SD (n=8 in each group). *P < 0.05 statistically significant difference vs. T 3 treatment.
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2+
-dependent SMase in muscle heart of hyperthyroid animals was reduced (Fig.3B , -71%, P < 0.05) compared to control. In contrast, prolonged T 3 treatment had no significant effect on acid SMase, although a trend towards an increase was noticed (Fig. 3B, +17% , P > 0.05). Subsequently, we observed that T 3 treatment had only a minor effect on the activity of either neutral or alkaline ceramidase in heart muscle ( Fig. 3A , P > 0.05).
AMPK and AKT activation
Subsequently, we investigated which cellular signaling pathways were activated by thyroid hormone treatment. We measured the ratio of phosphorylated to total form of both AMPK and AKT/PKB kinases in muscle hearts. In the hyperthyroidism, the level of AMPK ratio was markedly higher (Fig. 4A,+19% , P < 0.05) compared to the baseline values. However, the AKT ratio was not different between control and hyperthyroid hearts (Fig. 4B , P > 0.05).
The levels of mitochondrial protein -COX IV subunit, β-HAD or CPT I and regulator of mitochondrial biogenesis -PGC1α
We have also determined whether the hyperthyroidism evokes the changes in mitochondrial protein. We measured the COX IV, β-HAD, CPT I and PGC1α levels in heart muscle. COX IV and β-HAD protein contents were significantly increased (Fig. 4C, D , +40% and +30%, P < 0.05, respectively) in hyperthyroid hearts, and the level of CPT I protein as
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Discussion
The current study examined the effects of hyperthyroidism on sphingolipid metabolism in rat heart muscle. We have demonstrated that prolonged, in vivo, T 3 treatment increased the content of sphinganine, sphingosine, ceramide and sphingomyelin, but decreased the level of sphingosine-1-phosphate in cardiac myocytes. Accordingly, the changes in sphingolipids content were accompanied by decreased activity of neutral sphingomyelinase with no concomitant effects in ceramidases activities. This suggests, that although hyperthyroidism in the heart increases CER content, then it also tends to cause its conversion to sphingomyelin or sphingosine, which acts into opposite direction.
Previous studies showed that thyroid hormones can regulate cardiac metabolism via multiple cellular signaling pathways [1, 35] . Here we purpose also to include the sphingomyelin pathway. In our study, CER accumulation in the heart of hyperthyroid rats is due to either acidic SMase activation or enhanced de novo sphingolipid synthesis. The main support for this hypothesis comes from studies in which plasma concentration of free fatty acids increases during hyperthyroidism [18, 33] and as a consequence, their delivery to the heart also increases. This creates favorable conditions for increased ceramide synthesis, since it was shown that increased availability of extracellular palmitate was able to activate SPT-1, rate limiting enzyme for de novo synthesis of CER (Fig. 1) [13, 36, 37] . Furthermore, we observed that hyperthyroidism increased the activity of myocardial acid sphingomyelinase. This results, thereby, indicate that an enhancement in the content of CER was a consequence of increased formation of the compound from sphingomyelin. It seems that hyperthyroidism may increase activity of acidic SMase, which in turn elevates CER level, as has been reported for liver tissue homogenates, cultured hepatocytes [38] as well as in the adipose tissue of ob/ob mice [39] and high fat diet induced obesity in rodent models [40] . On the other hand, the present study also demonstrated that hyperthyroidism expressively increased sphingomyelin level. This would indicate that the rate of formation of sphingomyelin greatly exceeds the rate of its hydrolysis. Furthermore, an impact of neutral Mg 2+ dependent SMase, an enzyme producing ceramide from sphingomyelin can be excluded, as hyperthyroidism was accompanied by a significant decrease in this enzyme activity. It may indicate that during hyperthyreosis the synthesis of sphingomyelin is exacerbated via the de novo production of CER which can subsequently be converted into sphingomyelin. On the other hand, the augmented level of SM with the lower rate of its degradation indicates that a concurrent increase in the activity of sphingomyelin synthase was prevailing. In accordance with those previous statements, diminished content of ceramide and lack of changes in the sphingomyelin concentration in hearts of hypothyroid rats, was also reported [23] . On the other hand, ceramide not only exerts multiple biological effects per se, but also serves as a precursor for a production of other bioactive sphingolipids, such as sphingosine and sphingosine-1-phosphate. Interestingly, despite of the close structural homology of ceramide, sphingosine and S1P, the biological role of these lipids is different and in most cases even opposite [41] . It was found that hyperthyroidism induces accumulation of sphingosine in rat heart muscle. However, under basal conditions the content of myocardial sphinganine is markedly low as compared to sphingosine, especially since sphinganine is considered to be a key intermediate substrate in the de novo CER synthesis pathway and sphingosine is one of the major CER degradation product [14] . Therefore, it is likely that under T 3 stimulation sphinganine is phosphorylated preferentially over sphingosine which results in accumulation of the latter. It is important to note that the key destiny of sphingosine is phosphorylation with subsequent degradation [42] . Summing up it is likely that above mentioned effect(s) was a result of decreased rate of S1P formation from sphingosine. In line with this hypothesis, we observed a reduction of S1P content in heart muscle of rats
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Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry subjected to hyperthyroidism. The low level of S1P in cells is tightly regulated in a special manner by the balance between synthesis and degradation, which is the case for many other signaling molecules. Because the breakdown of S1P is the only way for cellular lipids to exit the sphingolipid pathway, therefore S1P may be quickly released to the extracellular environment, where it bounds to the S1P2 receptor subtype [37, 43] . Additionally, it is likely that following T 3 treatment, both intracellular S1P and SFO content rapidly exceeded CER levels suggesting rapid dephosphorylation of S1P to SFO. These data indicate that activation of ceramide catabolism may protect the heart against ceramide accumulation resulting from its augmented production de novo. During hyperthyroidism, relatively high rates of glucose use can be maintained in muscle heart despite the concomitant, marked elevations in the circulating concentrations of free fatty acids, altering the supply of substrates available to the heart for energy metabolism [1, 6] . It is widely accepted that increased plasma FFA availability which occurred during the hyperthyroidism leads to the accumulation of CER in tissues due to its augmented synthesis de novo. Studies in animal model of obesity and insulin resistant humans have demonstrated lipids accumulation in the heart and correlated these changes with potential mitochondrial dysfunction or apoptosis [44, 45] . Furthermore, fatty acid synthesis and oxidation in the heart are also regulated by thyroid hormones, which is initiated by binding of T 3 to nuclear its receptor. Researchers have shown that experimental hyperthyroidism results in increased mitochondrial protein synthesis most frequently in heart, liver, and oxidative skeletal muscle, but skeletal muscle with lower oxidative capacity appear to be less responsive to hyperthyroidism [8, 35] . The T 3 treated rats used in the present study had significantly higher level of mitochondrial cytochrome c oxidase (COX IV) as well as β-hydroxyacyl-CoA dehydrogenase (β-HAD), and trend to increase carnityne palmitoyltransferase I (CPT1). These proteins are involved in the regulation of muscle FA oxidation, but their relation to hyperthyroidism and sphingolipids accumulation are poorly understood. Although, a recent study, indicated that CPT I activity increases after T 3 treatment (3-7 days) as the result of lowered concentration of malonyl-CoA, a potent inhibitor of CPT I [46, 47] . Furthermore, the PGC1α transcriptional factor can also influence fatty acid oxidation rates via its overall regulation of mitochondrial biogenesis [1, 48] . However, some studies have shown that hyperthyroidism did no significant increase in cardiac PGC1α protein levels [1, 49] . Also, in the present study we observed just a trend to increase in the PGC1α content which was not statistically significant. Therefore, it is likely that T 3 maintaining a constant PGC1α level contribute to the control fatty acid oxidation in the hyperthyroid hearts.
Although most of the actions of thyroid hormones are mediated by changes in gene transcription, evidence has recently been provided indicating that triiodothyronine can activate AMP kinase acutely in heart via its membrane receptors [8, 10] . This effect was associated with increased intracellular Ca 2+ level, which subsequently increased contractility and enhanced energy demands. It is well established that AMPK acts as a fuel gauge for the cell, thus it is also an important regulator of myocardial energy metabolism by promoting glucose uptake and glycolysis as well as fatty acid oxidation [50] . Our research confirms that prolonged T 3 treatment has the ability to alter the phosphorylation status of AMP kinase in myocardium, tissue with high-oxidative capacity. However Irrcher et al. reported that phosphorylation of AMPK after 2 h T 3 treatment in heart was unaltered, while ERK 1/2 phosphorylation was decreased [8] . In our set prolonged T 3 administration most likely resulted in activation of AMPK with subsequently increased intracellular Ca 2+ level which further enhanced contractility and energy demands, provoking greater ATP utilization. This caused constant imbalance favoring AMPK activation, resulting in increased energy production as indicated by increased COX-IV and β-HAD mitochondrial proteins expression. On the other hand, it cannot be excluded that augmented FA demands together with enlarged FA availability, despite increased FA oxidation, might constantly contribute to intensification of de novo CER synthesis. To the best of our knowledge, there are no data in the literature addressing the influence of AMPK activation on the activity of enzymes involved in ceramide metabolism in heart muscle.
